- Home
- CHRS vs PFX Comparison
CHRS vs PFX Comparison
Compare CHRS & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- PFX
- Stock Information
- Founded
- CHRS 2010
- PFX 2010
- Country
- CHRS United States
- PFX United States
- Employees
- CHRS N/A
- PFX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- PFX Finance: Consumer Services
- Sector
- CHRS Health Care
- PFX Finance
- Exchange
- CHRS Nasdaq
- PFX Nasdaq
- Market Cap
- CHRS 112.5M
- PFX 101.2M
- IPO Year
- CHRS 2014
- PFX N/A
- Fundamental
- Price
- CHRS $0.76
- PFX $49.90
- Analyst Decision
- CHRS Strong Buy
- PFX
- Analyst Count
- CHRS 4
- PFX 0
- Target Price
- CHRS $5.26
- PFX N/A
- AVG Volume (30 Days)
- CHRS 1.7M
- PFX 1.1K
- Earning Date
- CHRS 05-12-2025
- PFX 05-06-2025
- Dividend Yield
- CHRS N/A
- PFX 5.48%
- EPS Growth
- CHRS N/A
- PFX N/A
- EPS
- CHRS N/A
- PFX 5.09
- Revenue
- CHRS $272,251,000.00
- PFX $24,036,577.00
- Revenue This Year
- CHRS N/A
- PFX $16.80
- Revenue Next Year
- CHRS N/A
- PFX $0.74
- P/E Ratio
- CHRS N/A
- PFX $9.83
- Revenue Growth
- CHRS 19.87
- PFX 15.02
- 52 Week Low
- CHRS $0.66
- PFX $43.80
- 52 Week High
- CHRS $2.43
- PFX $57.40
- Technical
- Relative Strength Index (RSI)
- CHRS 36.67
- PFX 46.57
- Support Level
- CHRS $0.71
- PFX $48.50
- Resistance Level
- CHRS $1.06
- PFX $50.52
- Average True Range (ATR)
- CHRS 0.08
- PFX 0.42
- MACD
- CHRS -0.03
- PFX 0.16
- Stochastic Oscillator
- CHRS 12.44
- PFX 52.25
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About PFX PhenixFIN Corporation
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.